Back

Patient Explorers

Aware

Current states

I am injecting BoNT-As, but I have not used Dysport®. I am satisfied with the BoNT-A I am currently using, and I believe Dysport® is more difficult to use.

Desired states

It is important to be able to use Dysport® so that I can help my patients achieve their goals. I am confident dosing and administering Dysport®.

A. Convince HCPs on benefits of Dysport®

B. Differentiate Dysport® based on lasting control

C. Provide reassurance in well-established safety profile

target

Messaging should be straight to the point, without complexity, with a focus on practical aspects of using Dysport®

Communication objective associated: Convince HCPs on benefits of Dysport®

  1. ~7 in 10 patients would like longer-lasting benefits
  2.  Nearly 9 in 10 of patients experience the early return of symptoms before their next injectio

Key supportive study :

  • Carenity study: Comella C, et al. J Neurol. 2021;268:903–912.

Key material:

  • CLM presentation

Digital material for follow up:

  • Burden of disease 

Communication objective associated: Convince HCPs on benefits of Dysport®

  1. Treatment-naïve patients experienced early and sustained benefits with the largest reduction in TWSTRS total scores between baseline and 6 months
  2. Dysport® is shown to be more effective for pain reduction vs ona-BoNT-A in CD
  3. Dysport® offers meaningful improvements in quality of life

Key supportive study:

  • Open label: Colosimo C, et al. J Neurol Sci. 2020;416:117015
  • Pain reduction:Mordin M, et al. BMJ Open. 2014;4(10):e005150

Key material:

  • CLM presentation

Digital material for follow up:

  • TBC

Communication objective associated: Differentiate Dysport® based on lasting control

  1. More than 40% patients did not require reinjecting before Week 16 of each treatment cycle
  2. Dysport® treatment can be tailored to suit each patient’s needs—optimizing dosing and injecting technique to create a better experience for the patient
  3. Recommended doses for upper/lower limb muscles

Key supportive study :

  • Esquenazi A, et al. Front Neurol. 2020;11:576117 Rehabil. 2024

Key material:

  • CLM presentation
  • Dosing app
  • FIT guide

Digital material for follow up:

  • TBC

Communication objective associated: Convince HCPs on benefits of Dysport®

  1. Dysport® contains more active neurotoxin within the licensed maximum dose than any other available BoNT-A
  2. The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered

Main key supportive study :

  • Field M, et al. Toxins. 2018;10:535

Key material

  • CLM presentation 
  • Dosing app
  • FIT guide

Digital material for follow up

  • TBC

Communication objective associated:Provide reassurance in well-established safety profile

  1. With 30 years of experience, Dysport® has a well-characterised safety profile at approved doses
  2. Dysport® offers a consistent safety profile across both low and high doses

Key material

  • CLM presentation

Communication objective associated:Convince HCPs on benefits of Dysport®

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early return of debilitating symptoms
  2. CLIMB: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. CLIMB website to support you in your training journey with Dysport

Key material

  • CLM presentation
  • Ixcellence website
  • FIT Guide